Standard Operating Procedure for Quality Control Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to establish a standardized procedure for the quality control testing of transdermal patches to ensure they meet the required specifications for safety, efficacy, and quality.

2) Scope

This SOP applies to all transdermal patches manufactured within the facility and intended for quality control testing, including but not limited to drug release rate, adhesion, thickness, and uniformity of dosage units.

3) Responsibilities

The Quality Control (QC) department is responsible for conducting and documenting all quality control tests on transdermal patches. The QC manager ensures compliance with this SOP and regulatory requirements.

4) Procedure

4.1 Preparation

• 4.1.1 Ensure all testing equipment is calibrated and in proper working condition.
• 4.1.2 Verify the availability of necessary reagents, standards, and reference materials.
• 4.1.3 Review the batch manufacturing record and sampling plan for the batch to be tested.

4.2 Sampling

• 4.2.1 Collect samples according to the approved sampling plan.
• 4.2.2 Label the samples appropriately and record the details in the sample logbook.

4.3 Testing Procedures

• 4.3.1 Drug Release Rate Testing:
  • 4.3.1.1 Prepare the dissolution medium as specified in the method.
  • 4.3.1.2 Place the transdermal patch in the dissolution apparatus.
  • 4.3.1.3 Collect samples at specified intervals and analyze using HPLC.
  • 4.3.1.4 Calculate the drug release rate and compare with the specifications.
• 4.3.2 Adhesion Testing:
  • 4.3.2.1 Use a texture analyzer to measure the force required to remove the patch from a standard substrate.
  • 4.3.2.2 Record the adhesion force and evaluate against the specifications.
• 4.3.3 Thickness Testing:
  • 4.3.3.1 Measure the thickness of the patch using a micrometer at different locations.
  • 4.3.3.2 Record the measurements and calculate the average thickness.
• 4.3.4 Uniformity of Dosage Units:
  • 4.3.4.1 Weigh individual patches to determine the uniformity of dosage units.
  • 4.3.4.2 Calculate the average weight and relative standard deviation (RSD).

4.4 Documentation

• 4.4.1 Record all test results in the appropriate QC data sheet.
• 4.4.2 Review and approve the test results before releasing the batch.
• 4.4.3 Retain all records and samples as per regulatory requirements.

5) Abbreviations, if any

HPLC: High-Performance Liquid Chromatography
QC: Quality Control
RSD: Relative Standard Deviation

6) Documents, if any

Batch Manufacturing Record
Sample Logbook
QC Data Sheets

7) Reference, if any

ICH Q2(R1) – Validation of Analytical Procedures: Text and Methodology
USP <905> Uniformity of Dosage Units

8) SOP Version

Version 1.0

Standard Operating Procedure for Packaging of Transdermal Patches

1) Purpose

The purpose of this SOP is to define the process for packaging transdermal patches to ensure product integrity, protection, and compliance with regulatory standards.

2) Scope

This SOP applies to all packaging activities related to transdermal patches within the facility, covering the preparation, packaging process, labeling, and final inspection.

3) Responsibilities

The Packaging Department is responsible for carrying out the packaging process as per this SOP. The Packaging Manager ensures adherence to the procedure and maintains the necessary documentation.

4) Procedure

4.1 Preparation

• 4.1.1 Verify the cleanliness and readiness of the packaging area and equipment.
• 4.1.2 Ensure all packaging materials are available and meet the required specifications.
• 4.1.3 Review the batch packaging record for completeness and accuracy.

4.2 Packaging Process

• 4.2.1 Primary Packaging:
  • 4.2.1.1 Load the transdermal patches into the designated packaging machine.
  • 4.2.1.2 Operate the machine to seal each patch in its individual pouch or blister pack.
  • 4.2.1.3 Inspect the sealed packages for defects or damage.
• 4.2.2 Secondary Packaging:
  • 4.2.2.1 Group the primary packaged units as per the packaging instructions.
  • 4.2.2.2 Place the grouped units into secondary cartons or boxes.
  • 4.2.2.3 Seal the cartons and label them appropriately.

4.3 Labeling

• 4.3.1 Verify the accuracy of all labels against the approved label copy.
• 4.3.2 Affix labels to the individual packages and secondary cartons as per the labeling instructions.
• 4.3.3 Inspect the labeled packages for legibility and correctness.

4.4 Final Inspection

• 4.4.1 Conduct a final inspection of the packaged units for compliance with specifications.
• 4.4.2 Document the inspection results in the packaging record.
• 4.4.3 Approve the packaged batch for release or document any deviations.

4.5 Documentation

• 4.5.1 Complete the batch packaging record with all relevant details.
• 4.5.2 Retain samples of the packaged product as per retention policy.
• 4.5.3 Archive all packaging records as per regulatory requirements.

5) Abbreviations, if any

None

6) Documents, if any

Batch Packaging Record
Label Copy Approval

7) Reference, if any

21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals
EU GMP Annex 15 – Qualification and Validation

8) SOP Version

Version 1.0

Standard Operating Procedure for Labeling of Transdermal Patches

1) Purpose

The purpose of this SOP is to define the procedure for labeling transdermal patches to ensure accurate and compliant labeling for identification, traceability, and regulatory adherence.

2) Scope

This SOP applies to all labeling activities for transdermal patches within the facility, including preparation, printing, application, and inspection of labels.

3) Responsibilities

The Labeling Department is responsible for executing the labeling process as per this SOP. The Labeling Manager ensures compliance with the procedure and regulatory requirements.

4) Procedure

4.1 Preparation

• 4.1.1 Verify the cleanliness and readiness of the labeling area and equipment.
• 4.1.2 Ensure the availability of approved label templates and materials.
• 4.1.3 Review the batch labeling record for accuracy and completeness.

4.2 Label Printing

• 4.2.1 Load the printer with the appropriate label stock.
• 4.2.2 Select the approved label template for the specific batch.
• 4.2.3 Print a test label and inspect for clarity, accuracy, and compliance.
• 4.2.4 Print the required number of labels for the batch.

4.3 Label Application

• 4.3.1 Verify the printed labels against the approved label copy.
• 4.3.2 Apply the labels to the primary and secondary packaging of the transdermal patches.
• 4.3.3 Ensure that the labels are affixed securely and correctly positioned.

4.4 Inspection and Verification

• 4.4.1 Conduct an inspection of the labeled packages to check for accuracy and legibility.
• 4.4.2 Verify the batch number, expiry date, and other critical information on the labels.
• 4.4.3 Document any discrepancies or deviations observed during inspection.

4.5 Documentation

• 4.5.1 Record all labeling activities in the batch labeling record.
• 4.5.2 Retain samples of labeled packages as per retention policy.
• 4.5.3 Archive all labeling records as per regulatory requirements.

5) Abbreviations, if any

None

6) Documents, if any

Batch Labeling Record
Approved Label Templates

7) Reference, if any

21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals
FDA Guidance for Industry: Labeling for Human Prescription Drug and Biological Products

8) SOP Version

Version 1.0

Standard Operating Procedure for Stability Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to outline the procedure for conducting stability testing of transdermal patches to ensure they meet the required quality standards over their shelf life.

2) Scope

This SOP applies to all stability testing activities for transdermal patches manufactured within the facility, including sample preparation, storage, testing, and documentation.

3) Responsibilities

The Stability Testing Department is responsible for performing and documenting stability tests as per this SOP. The Stability Testing Manager ensures compliance with this procedure and regulatory requirements.

4) Procedure

4.1 Sample Preparation

• 4.1.1 Select samples of transdermal patches from the production batch.
• 4.1.2 Label the samples with the batch number, manufacturing date, and storage condition.
• 4.1.3 Document the sample details in the stability testing logbook.

4.2 Storage Conditions

• 4.2.1 Store the samples under specified conditions (e.g., 25°C/60% RH, 30°C/65% RH, 40°C/75% RH).
• 4.2.2 Ensure the stability chambers are calibrated and maintain the required environmental conditions.
• 4.2.3 Monitor the storage conditions regularly and document any deviations.

4.3 Testing Schedule

• 4.3.1 Conduct stability tests at predetermined intervals (e.g., 0, 1, 3, 6, 9, 12 months, and annually thereafter).
• 4.3.2 Retrieve samples from the stability chambers as per the testing schedule.

4.4 Testing Procedures

• 4.4.1 Appearance:
  • 4.4.1.1 Inspect the samples for any changes in color, texture, or physical integrity.
  • 4.4.1.2 Document any observed changes.
• 4.4.2 Drug Content:
  • 4.4.2.1 Measure the active ingredient content using a validated analytical method (e.g., HPLC).
  • 4.4.2.2 Compare the results with the initial values and specification limits.
• 4.4.3 Adhesion:
  • 4.4.3.1 Perform adhesion testing as per the specified method.
  • 4.4.3.2 Record the adhesion force and compare with the initial results.
• 4.4.4 Release Rate:
  • 4.4.4.1 Conduct drug release testing using the appropriate dissolution method.
  • 4.4.4.2 Analyze the release profile and compare with the initial data.

4.5 Documentation

• 4.5.1 Record all test results in the stability testing data sheet.
• 4.5.2 Review and approve the stability data before archiving.
• 4.5.3 Retain stability samples and records as per regulatory requirements.

5) Abbreviations, if any

HPLC: High-Performance Liquid Chromatography
RH: Relative Humidity

6) Documents, if any

Stability Testing Logbook
Stability Testing Data Sheets

7) Reference, if any

ICH Q1A(R2) – Stability Testing of New Drug Substances and Products
USP <659> Packaging and Storage Requirements

8) SOP Version

Version 1.0

Standard Operating Procedure for Microbial Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to outline the procedure for conducting microbial testing of transdermal patches to ensure they meet the required microbiological quality standards.

2) Scope

This SOP applies to all microbial testing activities for transdermal patches manufactured within the facility, including sample collection, testing, and documentation.

3) Responsibilities

The Microbiology Laboratory is responsible for performing and documenting microbial tests as per this SOP. The Microbiology Manager ensures compliance with this procedure and regulatory requirements.

4) Procedure

4.1 Sample Collection

• 4.1.1 Select samples of transdermal patches from the production batch.
• 4.1.2 Label the samples with the batch number and date of collection.
• 4.1.3 Document the sample details in the microbial testing logbook.

4.2 Preparation

• 4.2.1 Prepare the necessary media, reagents, and equipment for testing.
• 4.2.2 Sterilize all equipment and work surfaces to prevent contamination.

4.3 Testing Procedures

• 4.3.1 Total Aerobic Microbial Count (TAMC):
  • 4.3.1.1 Homogenize the transdermal patch samples in a sterile diluent.
  • 4.3.1.2 Plate aliquots of the homogenate onto suitable agar plates.
  • 4.3.1.3 Incubate the plates at 30-35°C for 3-5 days.
  • 4.3.1.4 Count the number of colonies and record the TAMC.
• 4.3.2 Total Yeast and Mold Count (TYMC):
  • 4.3.2.1 Homogenize the transdermal patch samples in a sterile diluent.
  • 4.3.2.2 Plate aliquots of the homogenate onto Sabouraud Dextrose Agar plates.
  • 4.3.2.3 Incubate the plates at 20-25°C for 5-7 days.
  • 4.3.2.4 Count the number of colonies and record the TYMC.
• 4.3.3 Pathogen Testing:
  • 4.3.3.1 Test for specific pathogens (e.g., E. coli, S. aureus, P. aeruginosa) as per regulatory requirements.
  • 4.3.3.2 Use selective media and incubation conditions suitable for each pathogen.
  • 4.3.3.3 Record the presence or absence of each pathogen.

4.4 Interpretation of Results

• 4.4.1 Compare the microbial counts with the acceptance criteria.
• 4.4.2 Document any deviations or out-of-specification results.

4.5 Documentation

• 4.5.1 Record all test results in the microbial testing data sheet.
• 4.5.2 Review and approve the microbial data before archiving.
• 4.5.3 Retain samples and records as per regulatory requirements.

5) Abbreviations, if any

TAMC: Total Aerobic Microbial Count
TYMC: Total Yeast and Mold Count

6) Documents, if any

Microbial Testing Logbook
Microbial Testing Data Sheets

7) Reference, if any

USP <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests
USP <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms

8) SOP Version

Version 1.0

Standard Operating Procedure for Adhesion Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to define the procedure for conducting adhesion testing of transdermal patches to ensure they meet the required adhesion strength and quality standards.

2) Scope

This SOP applies to all adhesion testing activities for transdermal patches manufactured within the facility, including sample preparation, testing, and documentation.

3) Responsibilities

The Quality Control Department is responsible for performing and documenting adhesion tests as per this SOP. The QC Manager ensures compliance with the procedure and regulatory requirements.

4) Procedure

4.1 Sample Preparation

• 4.1.1 Select samples of transdermal patches from the production batch.
• 4.1.2 Condition the samples at 25°C and 60% RH for at least 24 hours before testing.
• 4.1.3 Label the samples with the batch number and date of preparation.
• 4.1.4 Document the sample details in the adhesion testing logbook.

4.2 Testing Equipment

• 4.2.1 Ensure the adhesion testing equipment (e.g., tensile tester) is calibrated and in proper working condition.
• 4.2.2 Set up the equipment according to the manufacturer’s instructions.

4.3 Testing Procedures

• 4.3.1 Peel Adhesion Test:
  • 4.3.1.1 Cut the transdermal patch into standard-sized strips (e.g., 25 mm x 150 mm).
  • 4.3.1.2 Apply each strip to a clean, dry, stainless steel panel using a roller.
  • 4.3.1.3 Allow the patches to adhere for 10 minutes.
  • 4.3.1.4 Mount the panel on the tensile tester and peel the patch at a 180° angle at a speed of 300 mm/min.
  • 4.3.1.5 Record the peel force and calculate the average peel adhesion strength.
• 4.3.2 Tack Test:
  • 4.3.2.1 Use a probe tack tester to measure the tack of the transdermal patch.
  • 4.3.2.2 Place the patch on the test surface and bring the probe into contact with the patch.
  • 4.3.2.3 Apply a specified force for a set dwell time (e.g., 1 second) and then withdraw the probe at a constant speed.
  • 4.3.2.4 Record the maximum force required to detach the probe from the patch surface.
• 4.3.3 Shear Adhesion Test:
  • 4.3.3.1 Cut the transdermal patch into standard-sized strips (e.g., 25 mm x 25 mm).
  • 4.3.3.2 Apply each strip to a clean, dry, stainless steel panel using a roller.
  • 4.3.3.3 Allow the patches to adhere for 10 minutes.
  • 4.3.3.4 Hang a specified weight (e.g., 1 kg) from the free end of the patch and start a timer.
  • 4.3.3.5 Record the time taken for the patch to shear off from the panel.

4.4 Interpretation of Results

• 4.4.1 Compare the adhesion strength with the acceptance criteria.
• 4.4.2 Document any deviations or out-of-specification results.

4.5 Documentation

• 4.5.1 Record all test results in the adhesion testing data sheet.
• 4.5.2 Review and approve the adhesion data before archiving.
• 4.5.3 Retain samples and records as per regulatory requirements.

5) Abbreviations, if any

RH: Relative Humidity

6) Documents, if any

Adhesion Testing Logbook
Adhesion Testing Data Sheets

7) Reference, if any

ASTM D3330/D3330M – Standard Test Method for Peel Adhesion of Pressure-Sensitive Tape
ISO 8510-2 – Adhesives – Peel Test for a Flexible-Bonded-to-Rigid Test Specimen Assembly – Part 2: 180 Degree Peel

8) SOP Version

Version 1.0

Standard Operating Procedure for Thickness Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to define the procedure for conducting thickness testing of transdermal patches to ensure they meet the required specifications.

2) Scope

This SOP applies to all thickness testing activities for transdermal patches manufactured within the facility, including sample preparation, testing, and documentation.

3) Responsibilities

The Quality Control Department is responsible for performing and documenting thickness tests as per this SOP. The QC Manager ensures compliance with the procedure and regulatory requirements.

4) Procedure

4.1 Sample Preparation

• 4.1.1 Select samples of transdermal patches from the production batch.
• 4.1.2 Condition the samples at 25°C and 60% RH for at least 24 hours before testing.
• 4.1.3 Label the samples with the batch number and date of preparation.
• 4.1.4 Document the sample details in the thickness testing logbook.

4.2 Testing Equipment

• 4.2.1 Ensure the thickness gauge or micrometer is calibrated and in proper working condition.
• 4.2.2 Set up the equipment according to the manufacturer’s instructions.

4.3 Testing Procedures

• 4.3.1 Thickness Measurement:
  • 4.3.1.1 Place the transdermal patch on a flat, hard surface.
  • 4.3.1.2 Use the thickness gauge or micrometer to measure the thickness at five different points on the patch (e.g., center, top, bottom, left, right).
  • 4.3.1.3 Record each measurement to the nearest 0.01 mm.
  • 4.3.1.4 Calculate the average thickness of the patch.

4.4 Interpretation of Results

• 4.4.1 Compare the average thickness with the specified limits.
• 4.4.2 Document any deviations or out-of-specification results.

4.5 Documentation

• 4.5.1 Record all test results in the thickness testing data sheet.
• 4.5.2 Review and approve the thickness data before archiving.
• 4.5.3 Retain samples and records as per regulatory requirements.

5) Abbreviations, if any

RH: Relative Humidity

6) Documents, if any

Thickness Testing Logbook
Thickness Testing Data Sheets

7) Reference, if any

ASTM D645 – Standard Test Method for Thickness of Paper and Paperboard
ISO 4593 – Plastics – Film and Sheeting – Determination of Thickness by Mechanical Scanning

8) SOP Version

Version 1.0

Standard Operating Procedure for Release Rate Testing of Transdermal Patches

1) Purpose

The purpose of this SOP is to outline the procedure for conducting release rate testing of transdermal patches to ensure they meet the required release rate specifications.

2) Scope

This SOP applies to all release rate testing activities for transdermal patches manufactured within the facility, including sample preparation, testing, and documentation.

3) Responsibilities

The Quality Control Department is responsible for performing and documenting release rate tests as per this SOP. The QC Manager ensures compliance with the procedure and regulatory requirements.

4) Procedure

4.1 Sample Preparation

• 4.1.1 Select samples of transdermal patches from the production batch.
• 4.1.2 Condition the samples at 25°C and 60% RH for at least 24 hours before testing.
• 4.1.3 Label the samples with the batch number and date of preparation.
• 4.1.4 Document the sample details in the release rate testing logbook.

4.2 Testing Equipment

• 4.2.1 Ensure the dissolution test apparatus (e.g., USP Apparatus 5 or 6) is calibrated and in proper working condition.
• 4.2.2 Set up the equipment according to the manufacturer’s instructions.

4.3 Testing Procedures

• 4.3.1 Release Rate Measurement:
  • 4.3.1.1 Mount the transdermal patch onto a suitable support (e.g., a stainless steel disc or holder).
  • 4.3.1.2 Place the mounted patch in the dissolution vessel containing the release medium (e.g., phosphate buffer, pH 7.4).
  • 4.3.1.3 Set the temperature of the dissolution medium to 32°C ± 0.5°C.
  • 4.3.1.4 Start the apparatus and maintain a constant stirring rate (e.g., 50 rpm).
  • 4.3.1.5 Collect samples of the dissolution medium at specified time intervals (e.g., 1, 2, 4, 6, 8, 12, and 24 hours).
  • 4.3.1.6 Replace the withdrawn volume with fresh dissolution medium to maintain a constant volume.
  • 4.3.1.7 Analyze the collected samples using an appropriate analytical method (e.g., HPLC) to determine the amount of active ingredient released.
• 4.3.2 Calculation of Release Rate:
  • 4.3.2.1 Calculate the cumulative amount of active ingredient released at each time point.
  • 4.3.2.2 Plot the cumulative release data against time to generate a release profile.
  • 4.3.2.3 Determine the release rate from the slope of the linear portion of the release profile.

4.4 Interpretation of Results

• 4.4.1 Compare the release rate with the specified limits.
• 4.4.2 Document any deviations or out-of-specification results.

4.5 Documentation

• 4.5.1 Record all test results in the release rate testing data sheet.
• 4.5.2 Review and approve the release rate data before archiving.
• 4.5.3 Retain samples and records as per regulatory requirements.

5) Abbreviations, if any

RH: Relative Humidity
HPLC: High-Performance Liquid Chromatography

6) Documents, if any

Release Rate Testing Logbook
Release Rate Testing Data Sheets

7) Reference, if any

USP <724> Drug Release
ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances

8) SOP Version

Version 1.0

Standard Operating Procedure for Storage Conditions of Transdermal Patches

1) Purpose

The purpose of this SOP is to define the procedures for storing transdermal patches to ensure they maintain their integrity, potency, and quality throughout their shelf life.

2) Scope

This SOP applies to the storage of all transdermal patches manufactured and stored within the facility, including raw materials, in-process materials, and finished products.

3) Responsibilities

The Warehouse Manager is responsible for ensuring the proper storage conditions of transdermal patches. All personnel involved in storage and handling must comply with this SOP.

4) Procedure

4.1 General Storage Requirements

• 4.1.1 Store transdermal patches in a clean, dry, and well-ventilated area.
• 4.1.2 Maintain storage areas free from pests, contaminants, and exposure to direct sunlight.
• 4.1.3 Segregate different types of products to avoid cross-contamination.
• 4.1.4 Ensure all storage shelves, racks, and pallets are clean and suitable for the storage of pharmaceutical products.

4.2 Temperature and Humidity Control

• 4.2.1 Store transdermal patches at controlled room temperature (15°C to 25°C) unless otherwise specified by the product label or manufacturer.
• 4.2.2 Monitor and record the temperature and humidity of the storage area daily using calibrated devices.
• 4.2.3 Maintain relative humidity (RH) between 30% and 65%.
• 4.2.4 If deviations occur, take corrective actions and document the incident.

4.3 Special Storage Conditions

• 4.3.1 Some transdermal patches may require refrigeration or freezing. Store such products according to the manufacturer’s instructions.
• 4.3.2 Use temperature-controlled storage units (e.g., refrigerators, freezers) for products requiring specific temperature conditions.
• 4.3.3 Monitor and document the temperature of refrigerated and frozen storage units daily.

4.4 Handling and Transportation

• 4.4.1 Handle transdermal patches with care to avoid physical damage.
• 4.4.2 Use appropriate containers and packaging materials for transporting patches to maintain storage conditions during transit.
• 4.4.3 Verify that transport vehicles are suitable and maintain the required storage conditions during transit.

4.5 Inventory Management

• 4.5.1 Rotate stock using the First-In-First-Out (FIFO) principle to ensure older stock is used before new stock.
• 4.5.2 Perform regular inventory checks to ensure accurate stock levels and identify expired or damaged products.
• 4.5.3 Dispose of expired or damaged transdermal patches according to the facility’s waste disposal procedures.

4.6 Documentation

• 4.6.1 Record all storage conditions and monitoring data in the storage logbook.
• 4.6.2 Maintain records of temperature and humidity monitoring, corrective actions, and inventory checks.
• 4.6.3 Retain documentation as per regulatory requirements.

5) Abbreviations, if any

RH: Relative Humidity
FIFO: First-In-First-Out

6) Documents, if any

Storage Logbook
Temperature and Humidity Monitoring Records
Inventory Records

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products
WHO Technical Report Series No. 992: Annex 5 – Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products

8) SOP Version

Version 1.0

Standard Operating Procedure for Cleaning of Equipment Used for Transdermal Patches

1) Purpose

The purpose of this SOP is to outline the procedures for cleaning equipment used in the manufacturing of transdermal patches to ensure compliance with GMP standards and to prevent contamination.

2) Scope

This SOP applies to all equipment used in the manufacturing of transdermal patches within the facility, including production and packaging equipment.

3) Responsibilities

The Production Department is responsible for cleaning the equipment according to this SOP. The Quality Assurance (QA) Department ensures compliance through routine audits and inspections.

4) Procedure

4.1 Cleaning Schedule

• 4.1.1 Clean equipment after each production batch or as specified in the equipment cleaning schedule.
• 4.1.2 Perform routine cleaning at the end of each shift or day.
• 4.1.3 Conduct deep cleaning and sanitization at regular intervals as specified (e.g., weekly, monthly).

4.2 Preparation for Cleaning

• 4.2.1 Turn off and unplug the equipment before cleaning.
• 4.2.2 Disassemble removable parts according to the manufacturer’s instructions.
• 4.2.3 Wear appropriate personal protective equipment (PPE) such as gloves, masks, and aprons.

4.3 Cleaning Process

• 4.3.1 Surface Cleaning:
  • 4.3.1.1 Remove any visible residue or product from the equipment surfaces using a clean, dry cloth.
  • 4.3.1.2 Apply an approved cleaning agent to a cloth or sponge and wipe down all surfaces.
  • 4.3.1.3 Rinse surfaces with clean water to remove any cleaning agent residues.
  • 4.3.1.4 Dry surfaces with a clean, lint-free cloth.
• 4.3.2 Parts Cleaning:
  • 4.3.2.1 Soak removable parts in a solution of approved cleaning agent.
  • 4.3.2.2 Scrub parts with a brush to remove any residues.
  • 4.3.2.3 Rinse parts thoroughly with clean water.
  • 4.3.2.4 Dry parts completely before reassembling.

4.4 Sanitization

• 4.4.1 Apply an approved sanitizing agent to the equipment surfaces and parts after cleaning.
• 4.4.2 Allow the sanitizing agent to remain in contact for the specified dwell time.
• 4.4.3 Rinse with clean water if required and dry the equipment.

4.5 Reassembly and Inspection

• 4.5.1 Reassemble the equipment according to the manufacturer’s instructions.
• 4.5.2 Inspect the equipment to ensure it is clean, dry, and free from any cleaning agent residues.

4.6 Documentation

• 4.6.1 Record all cleaning activities in the equipment cleaning logbook, including date, time, and personnel involved.
• 4.6.2 Document the cleaning agents and sanitizers used, including their concentrations and batch numbers.
• 4.6.3 Maintain records of routine and deep cleaning schedules.

5) Abbreviations, if any

GMP: Good Manufacturing Practice
PPE: Personal Protective Equipment
QA: Quality Assurance

6) Documents, if any

Equipment Cleaning Logbook
Cleaning and Sanitizing Agents Records

7) Reference, if any

FDA Guidance for Industry: Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients
EU GMP Annex 15: Qualification and Validation

8) SOP Version

Version 1.0